ATB 1606
Alternative Names: ATB-1606Latest Information Update: 04 Jul 2024
At a glance
- Originator AmtixBio
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Thymic stromal lymphopoietin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Atopic dermatitis; Inflammatory bowel diseases
Most Recent Events
- 16 Apr 2024 Preclinical trials in Atopic dermatitis in South Korea (unspecified route), prior to April 2024 (AmtixBio pipeline, April 2024)
- 16 Apr 2024 Preclinical trials in Inflammatory bowel diseases in South Korea (unspecified route), prior to April 2024 (AmtixBio pipeline, April 2024)
- 16 Apr 2024 AmtixBio plans a clinical trial in the first half of 2022 (AmtixBio pipeline, April 2024)